Traduction de «impairment alertness » (Anglais → Français) :

impairment of alertness

loss in value | asset impairment | decline in value | decrease in value | impairment | impairment in value | impairment loss | impairment of an asset | reduction in value

aspects and characteristics of hearing-impairment related communication | communication related to hearing impairments | communication related to hearing impairment | hearing-impairment related communication

rapid alert system for biological and chemical agent attacks | rapid alert system for biological and chemical agent attacks and threats | rapid alert system for biological and chemical agents and threats of terrorism | rapid alert system for biological and chemical attacks and threats | RAS-BICHAT [Abbr.]

impaired fasting glucose [ IFG | impaired fasting glycemia | impaired fasting glycaemia ]

impaired driving [ driving while impaired | driving while intoxicated | driving under the influence | driving under impairment ]

person who is hard of hearing | hard-of-hearing person | hearing impaired person | hard-of-hearing | aurally handicapped | hearing impaired | hearing-impaired

person with a visual impairment | visually impaired person | person with a visual disability | visually disabled person | visually impaired | visually disabled

alert level | alert state | security alert state

During a single occasion of use, the main risks are: (1) impaired alertness, accuracy, coordination and judgment in operating motor vehicles or other heavy machinery, and (2) occasional panic states or toxic psychoses caused by overdose.

With respect to impaired driving, for example, the road-side alert, which is the preliminary indicator, takes approximately 10 minutes.

They can be trained to pull wheel chairs, carry and pick up things for persons with mobility impairments, alert deaf individuals to sounds, and even dial the telephone in an emergency.

Q-26 — Mr. Cummins (Delta—South Richmond) — With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the ...[+++] Lariam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad sinc ...